• Important progress reported across the Nyrada therapeutic pipeline
• Potential first-in-class drugs in development for multiple large underserved indications, including cardiovascular disease, stroke and peripheral neuropathy
Sydney, 4 October 2018: Noxopharm (ASX:NOX) today releases a Report sent to the Convertible Note holders who in February 2018 provided $4 million in seed funding to Noxopharm subsidiary, Nyrada Inc. The Report provides an update on the Company’s progress over the last quarter across its three non-oncology drug development programs.
For further information please download PDF attached:
Download this document
